非小细胞肺癌术后辅助靶向治疗

国际肿瘤学杂志››2020,Vol. 47››Issue (4): 240-243.doi:10.3760/cma.j.cn371439-20191105-00010

非小细胞肺癌术后辅助靶向治疗

唐文洁^1,², 谢鹏²()

¹济南大学 betway.com 医学与生命科学学院,济南 250022
²山东省肿瘤防治研究院(山东省肿瘤医院)放疗科,betway必威登陆网址 (betway.com ),济南 250117

收稿日期:2019-11-05修回日期:2019-11-11出版日期:2020-04-08发布日期:2020-05-26
通讯作者:谢鹏 E-mail:xiepengro@126.com
基金资助:
国家自然科学基金(81502667);山东省重点研发计划(2016GSF201167)

Postoperative adjuvant targeted therapy for non-small cell lung cancer

Tang Wenjie^1,², Xie Peng²()

¹School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan 250022, China
²Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250117, China

Received:2019-11-05Revised:2019-11-11Online:2020-04-08Published:2020-05-26
Contact:Xie Peng E-mail:xiepengro@126.com
Supported by:
National Natural Science Foundation of China(81502667);Key Research and Development Plan of Shandong Province of China(2016GSF201167)

摘要/Abstract

摘要：

含铂双药化疗作为非小细胞肺癌(NSCLC)患者术后辅助治疗的主要手段之一,其临床疗效已达瓶颈,难以进一步改善患者生存。表皮生长因子受体(EGFR)酪氨酸激酶抑制剂目前已经成为EGFR敏感基因阳性晚期NSCLC患者的标准一线治疗,但其作为术后辅助治疗的价值目前尚不明确。近年国内外针对该领域开展了一些研究。

关键词:癌,非小细胞肺,分子靶向治疗,肿瘤辅助疗法

Abstract:

As one of the main methods of postoperative adjuvant therapy for non-small cell lung cancer (NSCLC) patients, the clinical effect of platinum-containing dual-drug chemotherapy has reached a ceiling effect and it is difficult to further improve the survival of patients with NSCLC. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors have become the standard first-line treatment for advanced NSCLC with EGFR mutation, but its value as postoperative adjuvant therapy is far to be investigated. Some studies have been carried out in this field in recent years.

Key words:Carcinoma,non-small-cell lung,Molecular targeted therapy,Neoadjuvant therapy

唐文洁, 谢鹏. 非小细胞肺癌术后辅助靶向治疗[J]. 国际肿瘤学杂志, 2020, 47(4): 240-243.

Tang Wenjie, Xie Peng. Postoperative adjuvant targeted therapy for non-small cell lung cancer[J]. Journal of International Oncology, 2020, 47(4): 240-243.

参考文献24

[1]	Bray F, Ferlay J, Soerjomataram I , et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. DOI: 10.3322/caac.21492. doi:10.3322/caac.v68.6
[2]	Chen W, Zheng R, Zeng H , et al. Annual report on status of cancer in China, 2011[J]. Chin J Cancer Res, 2015,27(1):2-12. DOI: 10.3978/j.issn.1000-9604.2015.01.06.
[3]	You R, Liu J, Wu DB , et al. Cost-effectiveness analysis of EGFR mutation testing and afatinib versus gemcitabine-cisplatin as first-line therapy for advanced non-small-cell lung cancer in China[J]. Cancer Manag Res, 2019,11:10239-10248. DOI: 10.2147/CMAR.S219722. doi:10.2147/CMAR
[4]	Goffin J, Lacchetti C, Ellis PM , et al. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review[J]. J Thorac Oncol, 2010,5(2):260-274. DOI: 10.1097/JTO.0b013e3181c6f035. doi:10.1097/JTO.0b013e3181c6f035
[5]	Ettinger DS, Wood DE, Akerley W , et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4. 2016[J]. J Natl Compr Canc Netw, 2016,14(3):255-264. DOI: 10.6004/jnccn.2016.0031. doi:10.6004/jnccn.2016.0031
[6]	Wu YL, Zhou C, Hu CP , et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial[J]. Lancet Oncol, 2014,15(2):213-222. DOI: 10.1016/S1470-2045(13)70604-1. doi:10.1016/S1470-2045(13)70604-1
[7]	Shi Y, Li J, Zhang S , et al. Molecular epidemiology of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology-mainland China subset analysis of the PIONEER study[J]. PLoS One, 2015,10(11):e0143515. DOI: 10.1371/journal.pone.0143515. doi:10.1371/journal.pone.0143515
[8]	Kim C, Liu SV . First-line EGFR TKI therapy in non-small cell lung cancer: looking back before leaping forward[J]. Ann Oncol, 2019,30(12):1852-1855. DOI: 10.1093/annonc/mdz415. doi:10.1093/annonc/mdz415
[9]	Goss GD, O'Callaghan C, Lorimer I, et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study[J]. J Clin Oncol, 2013,31(27):3320-3326. DOI: 10.1200/JCO.2013.51.1816. doi:10.1200/JCO.2013.51.1816
[10]	Kelly K, Altorki NK, Eberhardt WE , et al. Adjuvant erlotinib versus placebo in patients with stage ⅠB-ⅢA non-small-cell lung cancer (RADIANT): a randomized, double-blind, phase Ⅲ trial[J]. J Clin Oncol, 2015,33(34):4007-4014. DOI: 10.1200/JCO.2015.61.8918. doi:10.1200/JCO.2015.61.8918
[11]	Tsuboi M, Kato H, Nagai K , et al. Gefitinib in the adjuvant setting: safety results from a phase Ⅲ study in patients with completely resected non-small cell lung cancer[J]. Anticancer Drugs, 2005,16(10):1123-1128. DOI: 10.1097/00001813-200511000-00012. doi:10.1097/00001813-200511000-00012
[12]	Wu YL, Herbst RS, Mann H , et al. ADAURA: phase Ⅲ, double-blind, randomized study of osimertinib versus placebo in EGFR mutation-positive early-stage NSCLC after complete surgical resection[J]. Clin Lung Cancer, 2018,19(4):e533-e536. DOI: 10.1016/j.cllc.2018.04.004. doi:10.1016/j.cllc.2018.04.004
[13]	Janjigian YY, Park BJ, Zakowski MF , et al. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations[J]. J Thorac Oncol, 2011,6(3):569-575. DOI: 10.1097/JTO.0b013e318-202bffe. doi:10.1097/JTO.0b013e318202bffe
[14]	Li N, Ou W, Ye X , et al. Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage ⅢA-N₂non-small cell lung cancer harbouring EGFR mutations: a randomized, phase Ⅱ study[J]. Ann Surg Oncol, 2014,21(6):2091-2096. DOI: 10.1245/s10434-014-3586-9. doi:10.1245/s10434-014-3586-9
[15]	Feng S, Wang Y, Cai K , et al. Randomized adjuvant chemotherapy of EGFR-mutated non-small cell lung cancer patients with or without icotinib consolidation therapy[J]. PLoS One, 2015,10(10):e0140794. DOI: 10.1371/journal.pone.0140794. doi:10.1371/journal.pone.0140794
[16]	Pennell NA, Neal JW, Chaft JE , et al. SELECT: a phase Ⅱ trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small-cell lung cancer[J]. J Clin Oncol, 2019,37(2):97-104. DOI: 10.1200/JCO.18.00131.
[17]	Xie H, Wang H, Xu L , et al. Gefitinib versus adjuvant chemotherapy in patients with stage Ⅱ-ⅢA non-small-cell lung cancer harboring positive EGFR mutations: a single-center retrospective study[J]. Clin Lung Cancer, 2018,19(6):484-492. DOI: 10.1016/j.cllc.2018.05.007. doi:10.1016/j.cllc.2018.05.007
[18]	Lv C, An C, Feng Q , et al. A retrospective study of stage Ⅰ to Ⅲa lung adenocarcinoma after resection: what is the optimal adjuvant modality for patients with an EGFR mutation?[J]. Clin Lung Cancer, 2015,16(6):e173-e181. DOI: 10.1016/j.cllc.2015.04.002. doi:10.1016/j.cllc.2015.04.002
[19]	Zhong WZ, Wang Q, Mao WM , et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage Ⅱ-ⅢA (N₁-N₂) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study[J]. Lancet Oncol, 2018,19(1):139-148. DOI: 10.1016/S1470-2045(17)30729-5. doi:10.1016/S1470-2045(17)30729-5
[20]	Yue D, Xu S, Wang Q , et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage ⅢA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial[J]. Lancet Respir Med, 2018,6(11):863-873. DOI: 10.1016/S2213-2600(18)30277-7.
[21]	Uramoto H, Shimokawa H, Hanagiri T , et al. Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma[J]. Lung Cancer, 2011,73(3):361-365. DOI: 10.1016/j.lungcan.2011.01.008.
[22]	Liu D, Yang Y, Zhao S . Autophagy facilitates the EGFR-TKI acquired resistance of non-small-cell lung cancer cells[J]. J Formos Med Assoc, 2014,113(3):141-142. DOI: 10.1016/j.jfma.2012.10.017.
[23]	Westover D, Zugazagoitia J, Cho BC , et al. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors[J]. Ann Oncol, 2018,29(suppl_1):i10-i19. DOI: 10.1093/annonc/mdx703.
[24]	Hsu WH, Yang JC, Mok TS , et al. Overview of current systemic management of EGFR-mutant NSCLC[J]. Ann Oncol, 2018,29(suppl_1):i3-i9. DOI: 10.1093/annonc/mdx702.